iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 06, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:
H.C. Wainwright 25th Annual Global Investment Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, September 13, 2023
Time: 12:30 – 1:00 PM ET
Location: New York, N.Y.
Cantor Global Healthcare Conference 2023
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, September 27, 2023
Time: 8:35 – 9:35 AM ET
Location: New York, N.Y.
A live webcast of each presentation will be available on the Investors section of the company’s website at . An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT:CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos Therapeutics routinely posts information that may be important to investors in the 'Investors' section of its website at The company encourages investors and potential investors to consult our website regularly for important information about iTeos Therapeutics.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
Media Contact:
